Cambrex Completes Expansion of Snapdragon Chemistry Facility in Waltham, Massachusetts
East Rutherford, NJ (May 16, 2022) – Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that that Snapdragon Chemistry has completed the second phase of its 51,000 square foot expansion in Waltham, Massachusetts.
This expansion adds an additional 12,000 square feet to Snapdragon’s active pharmaceutical ingredient (API) development and manufacturing facility, including new process research and development suites with 24 hoods, a GMP stability suite, and a fifth GMP kilo-lab, designed for multi-step, end-to-end continuous processing.
"We are pleased to see Cambrex’s ongoing commitment to providing best-in-class API process development services, supporting the completion of this expansion following our recent acquisition" -Matt Bio, CEO of Snapdragon Chemistry
Read the Full Press Release Below